ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
$ZVSA
Biotechnology: Pharmaceutical Preparations
Health Care
ZyVersa Therapeutics Shares Resume Trade Following Circuit Breaker Halt
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
10-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
8-K - ZyVersa Therapeutics, Inc. (0001859007) (Filer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
4 - ZyVersa Therapeutics, Inc. (0001859007) (Issuer)
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress
ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases.The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease.The lead indication for IC 100 is cardiometabolic conditions, with potential indication expansion in rare kidney diseases.Raised approximately $2.05 million in Q3-2025; $4.05 million year-to-date. WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Th
Type 2 diabetes (T2DM), affecting more than 530 million worldwide, is a metabolic disease often coupled with cardiovascular complications including coronary artery disease, heart failure, and stroke.Cardiovascular complications are a leading cause of disability and death in people with T2DM. People with T2DM are 2 to 4 times more likely to experience cardiovascular events than people without T2DM, and post-event outcomes are often worse. About half of all diabetes-related fatalities can be attributed to cardiovascular causes.The published data provide evidence that inflammasome-induced inflammation plays a central role in the development and progression of T2DM and its cardiovascular complic
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal diseases with a total accessible market >$100 billion.Inflammasome ASC Inhibitor IC 100 is a next generation drug designed for unparalleled control of disease-causing inflammation by (1) inhibiting multiple inflammasomes activated in numerous diseases, not just NLRP3, and (2) attenuating spread and perpetuation of inflammation by uniquely inhibiting ASC specks. Lead indication: Cardiometabolic conditions associated with obesityValue driving milestones: File IND Q4-2026; Phase 1 SAD read-out Q1-2027 Cholesterol Efflux Mediator VAR 200 is expected to be a disease-modifying renal drug by targeting unaddress
ZyVersa is advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100 for treatment of chronic inflammatory diseases.The lead indication for VAR 200 is focal segmental glomerulosclerosis (FSGS) with potential indication expansion in Alport syndrome and diabetic kidney disease.The lead indication for IC 100 is cardiometabolic conditions, with potential indication expansion in rare kidney diseases.Raised approximately $2.05 million in Q3-2025; $4.05 million year-to-date. WESTON, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- ZyVersa Th
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIR
SC 13G/A - ZyVersa Therapeutics, Inc. (0001859007) (Subject)